PRESS RELEASE

Q4 2020 — Press release

Q4 2020PDF · 17 pages423 KB
JOHNSON & JOHNSON REPORTS 2020 FOURTH-QUARTER AND FULL YEAR RESULTS:
• 	2020 Fourth-Quarter Sales of $22.5 Billion reflecting growth of 8.3%, operational growth of
7.1%* and adjusted operational growth of 7.3%*
• 	2020 Full-Year Sales of $82.6 Billion reflecting growth of 0.6%, operational growth of 1.2%* and
adjusted operational growth of 1.5%*
• 	2020 Fourth-Quarter EPS of $0.65 decreased 56.7%; adjusted EPS of $1.86 decreased 1.1%*
• 	2020 Full-Year EPS of $5.51 decreased 2.1%; adjusted EPS of $8.03 decreased 7.5%*
• 	Company provides 2021 guidance of adjusted operational sales growth of 8.8%* and adjusted
operational EPS growth of 16.4%*
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-
quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients,
physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the
COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson
& Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our
commitment to families around the world as the largest broad-based healthcare company, enabled us to lead in the
fight against COVID-19. We continue to progress our COVID-19 vaccine candidate and look forward to sharing
details from our Phase 3 study soon. Johnson & Johnson was built for times like these, and I am extremely confident
in our ability to deliver lasting value and continued innovation in 2021 and for years to come.”
OVERALL FINANCIAL RESULTS:
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items
($ in Millions, except EPS) 	2020 	2019 	% Change 	2020 	2019 	% Change
Reported Sales 	22,475	$ 	20,747	$ 	8.3% 	82,584	$ 	82,059	$ 	0.6%
Net Earnings 	1,738 	4,010 	(56.7)% 	14,714 	15,119 	(2.7)%
EPS (diluted) 	0.65	$ 	1.50	$ 	(56.7)% 	5.51	$ 	5.63	$ 	(2.1)%
Non-GAAP*
($ in Millions, except EPS) 	2020 	2019 	% Change 	2020 	2019 	% Change
Operational Sales 1,2 	7.1% 	1.2%
Adjusted Operational Sales 1,3 	7.3% 	1.5%
Adjusted Net Earnings 1,4 	4,965 	5,027 	(1.2)% 	21,433 	23,310 	(8.1)%
Adjusted EPS (diluted) 1,4 	1.86	$ 	1.88	$ 	(1.1)% 	8.03	$ 	8.68	$ 	(7.5)%
FOURTH QUARTER
FOURTH QUARTER 	TWELVE MONTHS
TWELVE MONTHS

-- 1 of 17 --

2
REGIONAL SALES RESULTS:
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
SEGMENT SALES RESULTS:
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Adjusted
($ in Millions) 1
Adjusted
2020 2
Adjusted
2019 2
Adjusted
Reported 2
Adjusted
Operational 1,2
Adjusted
Currency2
Adjusted
Operational 1,3
U.S. 	11,809	$ 	10,774	$ 	9.6% 	9.6% 	- 	9.6
International 	10,666 	9,973 	7.0% 	4.3% 	2.7 	4.8
Worldwide 	22,475	$ 	20,747	$ 	8.3% 	7.1% 	1.2 	7.3
Adjusted
($ in Millions) 1
Adjusted
2020 2
Adjusted
2019 2
Adjusted
Reported 2
Adjusted
Operational 1,2
Adjusted
Currency2
Adjusted
Operational 1,3
U.S. 	43,133	$ 	42,097	$ 	2.5% 	2.5 	- 	2.8
International 	39,451 	39,962 	(1.3)% 	(0.2) 	(1.1) 	0.2
Worldwide 	82,584	$ 	82,059	$ 	0.6% 	1.2 	(0.6) 	1.5
FOURTH QUARTER 	% Change
TWELVE MONTHS 	% Change
Adjusted
($ in Millions) 1
Adjusted
2020 1
Adjusted
2019 1
Adjusted
Reported2
Adjusted
Operational 1,2
Adjusted
Currency1
Adjusted
Operational 1,3
Consumer Health 	3,618	$ 	3,567	$ 	1.4% 	2.0 	(0.6) 	2.1
Pharmaceutical 	12,268 	10,548 	16.3% 	14.6 	1.7 	14.6
Medical Devices 	6,589 	6,632 	(0.7)% 	(2.2) 	1.5 	(1.5)
Worldwide 	22,475	$ 	20,747	$ 	8.3% 	7.1 	1.2 	7.3
Adjusted
($ in Millions) 1
Adjusted
2020 1
Adjusted
2019 1
Adjusted
Reported2
Adjusted
Operational 1,2
Adjusted
Currency1
Adjusted
Operational 1,3
Consumer Health 	14,053	$ 	13,898	$ 	1.1% 	3.0 	(1.9) 	3.1
Pharmaceutical 	45,572 	42,198 	8.0% 	8.2 	(0.2) 	8.4
Medical Devices 	22,959 	25,963 	(11.6)% 	(11.4) 	(0.2) 	(10.5)
Worldwide 	82,584	$ 	82,059	$ 	0.6% 	1.2 	(0.6) 	1.5
% Change	FOURTH QUARTER
TWELVE MONTHS 	% Change

-- 2 of 17 --

3
FULL-YEAR 2020 SEGMENT COMMENTARY:
Consumer Health
Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 3.1%*
driven by U.S. growth in over-the-counter products including TYLENOL analgesics, PEPCID and ZYRTEC; LISTERINE
mouthwash in oral care products; OGX in skin health/beauty products and wound care products. 	Growth was
negatively impacted by COVID-19 primarily in skin health/beauty and international baby care partially offset by
increased COVID-19 demand in oral care products.
Pharmaceutical
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.4%*
driven by STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory
diseases, DARZALEX (daratumumab), for the treatment of multiple myeloma, IMBRUVICA (ibrutinib), an oral, once-
daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, ERLEADA
(apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer,
TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for
adults with active psoriatic arthritis, 	INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone
palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, OPSUMIT
(macitentan), an oral endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension to
delay disease progression and UPTRAVI (selexipag), an oral prostacyclin receptor agonist used to treat pulmonary
arterial hypertension and reduce hospitalization. This growth was partially offset by the negative impact of COVID-19
as well as biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved
for the treatment of a number of immune-mediated inflammatory diseases, U.S. ZYTIGA (abiraterone acetate), an oral,
once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant
prostate cancer, and international VELCADE (bortezomib), a proteasome inhibitor for the treatment of multiple
myeloma.
Medical Devices
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined by
10.5%*. The decline was primarily driven by the negative impact of the COVID-19 pandemic and the associated deferral
of 	medical 	procedures 	to 	our 	Surgery, 	Orthopaedics, 	and 	Vision 	businesses. 	The 	decline was partially
offset by growth in the Interventional Solutions business led by electrophysiology products. Results reflect market
recovery in the second half of 2020.

-- 3 of 17 --

4
NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures
filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on
Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news
releases available online in the Investors section of the company’s website at news releases.
Regulatory
Approvals
VELYS Robotic-Assisted Solution- Receives 510(k) FDA Clearance Designed for Use with
the ATTUNE Total Knee System ¹ (press release)
DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)- Becomes the First FDA-
Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis ¹ (press release)
CABENUVA (rilpivirine/cabotegravir)- U.S. FDA Approval and European Commission
Authorization of the first complete long acting injectable HIV treatment ¹
(press release)
(press release)
TREMFYA (guselkumab)- European Commission Approves First-in-Class treatment for
Active Psoriatic Arthritis (PsA) (press release)
Regulatory
Submissions
Amivantamab- Submission of U.S. FDA and European Marketing Authorization Application
for Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20
Insertion Mutations
(press release)
(press release)
BCMA CAR-T Therapy (ciltacabtagene autoleucel)- Rolling Submission of a Biologics
License Application to U.S. FDA for the Treatment of Relapsed and/or Refractory Multiple
Myeloma
(press release)
DARZALEX (daratumumab and hyaluronidase-fihj)- Janssen Submits Applications in U.S.
and EU Seeking Approval of DARZALEX FASPRO (daratumumab and hyaluronidase-
fihj)/DARZALEX (daratumumab) Subcutaneous (SC) Formulation in Combination With
Pomalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple
Myeloma
(press release)
Paliperidone Palmitate 6-Month- Submission of Supplemental New Drug Application to U.S.
FDA and European Marketing Authorization for Treatment of Schizophrenia in Adults
(press release)
(press release)
XARELTO (rivaroxaban)- Submission of Application to U.S. FDA for New Indication to
Expand Use in Patients with Peripheral Artery Disease (press release)
Other
Janssen Receives Positive CHMP Opinion for SPRAVATO (esketamine Nasal Spray) for
the Rapid Reduction of Depressive Symptoms in a Psychiatric Emergency for Patients with
Major Depressive Disorder
(press release)
Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-
Stage Age-Related Macular Degeneration (press release)
Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19
Vaccine Candidate (press release)
1 Subsequent to the quarter

-- 4 of 17 --

5
FULL-YEAR 2021 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is
unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses,
acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items
are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in
accordance with GAAP.
January 2021
($ in Billions, except EPS)
Adjusted Operational Sales1,2
Change vs. Prior Year 8.0% - 9.5%
Operational Sales 2
Change vs. Prior Year
$88.8B - $90.0B
7.5% – 9.0%
Estimated Reported Sales 3
Change vs. Prior Year
$90.5B - $91.7B
9.5% – 11.0%
Adjusted Operational EPS (Diluted) 2,4
Change vs. Prior Year
$9.25 - $9.45
15.2% - 17.7%
Adjusted EPS (Diluted) 3,4
Change vs. Prior Year
$9.40 - $9.60
17.1% - 19.6%
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: January 2021 = $1.21 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
Other modeling considerations will be provided on the webcast.
WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m.,
Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting
the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast
in the Investors section of the company's website at events-and-presentations.
ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward
progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life.
Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and
size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind,
body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to
profoundly change the trajectory of health for humanity.

-- 5 of 17 --

6
NON-GAAP FINANCIAL MEASURES:
*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding
the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted
diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible
amortization expense and special items, are non-GAAP financial measures and should not be considered
replacements for, and should be read together with, the most comparable GAAP financial measures. Except for
guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP
financial measures can be found in the accompanying financial schedules of the earnings release and the Investors
section of the company's website at quarterly-results.
Copies of the financial schedules accompanying this earnings release are available on the company’s website at
quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of
earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information
on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected
compounds in late stage development and a copy of today’s earnings call presentation can also be found in the
Investors section of the company's website at quarterly-results.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of
1995 regarding, among other things: future operating and financial performance, product development, market position
and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are
based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks
or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson &
Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global
pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented
in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to
the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic,
economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological
advances, new products and patents attained by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial
success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the
Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls
or regulatory action; significant adverse litigation or government action, including related to product liability claims;
changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health
care cost containment; changes in behavior and spending patterns of purchasers of health care products and services;
financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health
care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can
be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including
in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in
the Company’s most recently filed Quarterly Report on Form 10-Q and the Company’s subsequent filings with the
Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on
request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of
this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new
information or future events or developments.
Press Contacts: 	Investor Contacts:
Christina Chan 	Courtney Dugan 	Christopher DelOrefice 	Lisa Romanko
(732) 524-6297 	(347) 452-1061 	(732) 524-2955 	(732) 524-2034

-- 6 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2020 	2019 	Total 	Operations 	Currency 	2020 	2019 	Total 	Operations 	Currency
Sales to customers by
segment of business
Consumer Health
U.S. 	1,509	$ 	1,470 	2.7 % 	2.7 	- 	6,362	$ 	5,839 	9.0 % 	9.0 	-
International 	2,109 	2,097 	0.5 	1.5 	(1.0) 	7,691 	8,059 	(4.6) 	(1.3) 	(3.3)
3,618 	3,567 	1.4 	2.0 	(0.6) 	14,053 	13,898 	1.1 	3.0 	(1.9)
Pharmaceutical
U.S. 	7,116 	6,169 	15.3 	15.3 	- 	25,735 	23,874 	7.8 	7.8 	-
International 	5,152 	4,379 	17.7 	13.5 	4.2 	19,837 	18,324 	8.3 	8.8 	(0.5)
12,268 	10,548 	16.3 	14.6 	1.7 	45,572 	42,198 	8.0 	8.2 	(0.2)
Medical Devices
U.S. 	3,184 	3,135 	1.5 	1.5 	- 	11,036 	12,384 	(10.9) 	(10.9) 	-
International 	3,405 	3,497 	(2.6) 	(5.5) 	2.9 	11,923 	13,579 	(12.2) 	(11.8) 	(0.4)
6,589 	6,632 	(0.7) 	(2.2) 	1.5 	22,959 	25,963 	(11.6) 	(11.4) 	(0.2)
U.S. 	11,809 	10,774 	9.6 	9.6 	- 	43,133 	42,097 	2.5 	2.5 	-
International 	10,666 	9,973 	7.0 	4.3 	2.7 	39,451 	39,962 	(1.3) 	(0.2) 	(1.1)
Worldwide 	22,475	$ 	20,747 	8.3 % 	7.1 	1.2 	82,584	$ 	82,059 	0.6 % 	1.2 	(0.6)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
TWELVE MONTHS
Percent Change
FOURTH QUARTER

-- 7 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2020 	2019 	Total 	Operations 	Currency 	2020 	2019 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	11,809	$ 	10,774 	9.6 % 	9.6 	- 	43,133	$ 	42,097 	2.5 % 	2.5 	-
Europe 	5,271 	4,663 	13.0 	7.7 	5.3 	18,980 	18,466 	2.8 	2.0 	0.8
Western Hemisphere excluding U.S. 	1,404 	1,495 	(6.1) 	2.9 	(9.0) 	5,335 	5,941 	(10.2) 	0.4 	(10.6)
Asia-Pacific, Africa 	3,991 	3,815 	4.6 	0.7 	3.9 	15,136 	15,555 	(2.7) 	(3.1) 	0.4
International 	10,666 	9,973 	7.0 	4.3 	2.7 	39,451 	39,962 	(1.3) 	(0.2) 	(1.1)
Worldwide 	22,475	$ 	20,747 	8.3 % 	7.1 	1.2 	82,584	$ 	82,059 	0.6 % 	1.2 	(0.6)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FOURTH QUARTER 	TWELVE MONTHS
Percent Change

-- 8 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	22,475	$ 	100.0 	20,747	$ 	100.0 	8.3
Cost of products sold 	7,814 	34.8 	7,134 	34.4 	9.5
Gross Profit 	14,661 	65.2 	13,613 	65.6 	7.7
Selling, marketing and administrative expenses 	6,457 	28.7 	6,039 	29.1 	6.9
Research and development expense 	4,032 	17.9 	3,232 	15.6 	24.8
In-process research and development 	37 	0.2 	- 	-
Interest (income) expense, net 	74 	0.3 	4 	0.0
Other (income) expense, net 	2,354 	10.5 	16 	0.1
Restructuring 	60 	0.3 	104 	0.5
Earnings before provision for taxes on income 	1,647 	7.3 	4,218 	20.3 	(61.0)
Provision for/(Benefit from) taxes on income 	(91) 	(0.4) 	208 	1.0 	(143.8)
Net earnings 	1,738	$ 	7.7 	4,010	$ 	19.3 	(56.7)
Net earnings per share (Diluted) 	0.65	$ 	1.50	$ 	(56.7)
Average shares outstanding (Diluted) 	2,669.2 	2,669.1
Effective tax rate 	(5.5) % 	4.9 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	5,601	$ 	24.9 	5,628	$ 	27.1 	(0.5)
Net earnings 	4,965	$ 	22.1 	5,027	$ 	24.2 	(1.2)
Net earnings per share (Diluted) 	1.86	$ 	1.88	$ 	(1.1)
Effective tax rate 	11.4 % 	10.7 %
(1) See Reconciliation of Non-GAAP Financial Measures.
FOURTH QUARTER
2020 	2019

-- 9 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	82,584	$ 	100.0 	82,059	$ 	100.0 	0.6
Cost of products sold 	28,427 	34.4 	27,556 	33.6 	3.2
Gross Profit 	54,157 	65.6 	54,503 	66.4 	(0.6)
Selling, marketing and administrative expenses 	22,084 	26.8 	22,178 	27.0 	(0.4)
Research and development expense 	12,159 	14.7 	11,355 	13.8 	7.1
In-process research and development 	181 	0.2 	890 	1.1
Interest (income) expense, net 	90 	0.1 	(39) 	0.0
Other (income) expense, net 	2,899 	3.5 	2,525 	3.1
Restructuring 	247 	0.3 	266 	0.3
Earnings before provision for taxes on income 	16,497 	20.0 	17,328 	21.1 	(4.8)
Provision for taxes on income 	1,783 	2.2 	2,209 	2.7 	(19.3)
Net earnings 	14,714	$ 	17.8 	15,119	$ 	18.4 	(2.7)
Net earnings per share (Diluted) 	5.51	$ 	5.63	$ 	(2.1)
Average shares outstanding (Diluted) 	2,670.7 	2,684.3
Effective tax rate 	10.8 % 	12.7 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	25,428	$ 	30.8 	28,225	$ 	34.4 	(9.9)
Net earnings 	21,433	$ 	26.0 	23,310	$ 	28.4 	(8.1)
Net earnings per share (Diluted) 	8.03	$ 	8.68	$ 	(7.5)
Effective tax rate 	15.7 % 	17.4 %
(1) See Reconciliation of Non-GAAP Financial Measures.
TWELVE MONTHS
2020 	2019

-- 10 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2020 	2019 	2020 	2019
Net Earnings, after tax- as reported 	$1,738 	$4,010 	$14,714 	$15,119
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,234 	1,142 	4,660 	4,528
Litigation expense, net 	2,902 	264 	5,112 	5,096
IPR&D 	37 	- 	181 	890
Restructuring related 	85 	251 	448 	611
Acquisition and Integration related ¹ 	14 	90 	(1,073) 	319
Unrealized (gains)/losses on securities 	(373) 	(350) 	(547) 	(567)
Medical Device Regulation 2 	55 	- 	144 	-
Other 	- 	13 	6 	20
Tax Adjustments
Tax impact on special item adjustments 3 	(606) 	(123) 	(1,608) 	(1,977)
Tax legislation and other tax related 	(121) 	(270) 	(604) 	(729)
Adjusted Net Earnings, after tax 	$4,965 	$5,027 	$21,433 	$23,310
Average shares outstanding (Diluted) 	2,669.2 	2,669.1 	2,670.7 	2,684.3
Adjusted net earnings per share (Diluted) 	$1.86 	$1.88 	$8.03 	$8.68
Operational adjusted net earnings per share (Diluted) 	$1.82 	$8.00
Notes:
1
2
3
Prior year amounts have been reclassified to conform to current year disclosure
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the
above pre-tax special items in arriving at adjusted earnings.
Fourth Quarter 	Twelve Months Ended
Acquisition and integration related costs for 2020 primarily includes a Contingent Consideration reversal of $1,148M
related to the timing of certain developmental milestones associated with the Auris Health acquisition.
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously
registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework,
and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021.
The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of
on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its
Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing
performance.

-- 11 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	1.4% 	16.3% 	(0.7)% 	8.3%
U.S. 	2.7% 	15.3% 	1.5% 	9.6%
International 	0.5% 	17.7% 	(2.6)% 	7.0%
WW Currency 	(0.6) 	1.7 	1.5 	1.2
U.S. 	- 	- 	- 	-
International 	(1.0) 	4.2 	2.9 	2.7
WW Operational 	2.0% 	14.6% 	(2.2)% 	7.1%
U.S. 	2.7% 	15.3% 	1.5% 	9.6%
International 	1.5% 	13.5% 	(5.5)% 	4.3%
General Surgery
Advanced Sterilization Products 	0.6 	0.2
U.S. 	0.0 	0.0
International 	1.0 	0.4
All Other Acquisitions and Divestitures 	0.1 	0.0 	0.1 	0.1
U.S. 	0.1 	(0.1) 	0.2 	0.0
International 	0.1 	0.2 	0.0 	0.1
WW Adjusted Operational 	2.1% 	14.6% 	(1.5)% 	7.3%
U.S. 	2.8% 	15.2% 	1.7% 	9.6%
International 	1.6% 	13.7% 	(4.4)% 	4.8%
Adjusted Operational Sales Growth
FOURTH QUARTER 2020 ACTUAL vs. 2019 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 12 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	1.1% 	8.0% 	(11.6)% 	0.6%
U.S. 	9.0% 	7.8% 	(10.9)% 	2.5%
International 	(4.6)% 	8.3% 	(12.2)% 	(1.3)%
WW Currency 	(1.9) 	(0.2) 	(0.2) 	(0.6)
U.S. 	- 	- 	- 	-
International 	(3.3) 	(0.5) 	(0.4) 	(1.1)
WW Operational 	3.0% 	8.2% 	(11.4)% 	1.2%
U.S. 	9.0% 	7.8% 	(10.9)% 	2.5%
International 	(1.3)% 	8.8% 	(11.8)% 	(0.2)%
Skin Health / Beauty
Dr. Ci Labo - Japan 	(0.1) 	0.0
U.S. 	0.0 	0.0
International 	(0.2) 	0.0
General Surgery
Advanced Sterilization Products 	0.8 	0.3
U.S. 	0.6 	0.2
International 	1.0 	0.4
Baby Care
Baby Center 	0.2 	0.0
U.S. 	0.5 	0.1
International 	0.0 	0.0
All Other Acquisitions and Divestitures 	0.0 	0.2 	0.0 	0.1
U.S. 	0.0 	0.0 	0.0 	0.0
International 	(0.1) 	0.3 	0.0 	0.1
WW Adjusted Operational 	3.1% 	8.4% 	(10.5)% 	1.5%
U.S. 	9.5% 	7.8% 	(10.2)% 	2.8%
International 	(1.5)% 	9.1% 	(10.9)% 	0.2%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
TWELVE MONTHS 2020 ACTUAL vs. 2019 ACTUAL
Segments

-- 13 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
CONSUMER HEALTH SEGMENT (2,3)
OTC
US 	543	$ 	542 	0.1% 	0.1% 	- 	2,460	$ 	2,010 	22.4% 	22.4% 	-
Intl 	642 	653 	-1.7% 	-2.9% 	1.2% 	2,364 	2,434 	-2.9% 	-1.2% 	-1.7%
WW 	1,185 	1,195 	-0.8% 	-1.5% 	0.7% 	4,824 	4,444 	8.5% 	9.4% 	-0.9%
SKIN HEALTH / BEAUTY
(4)
US 	583 	582 	0.2% 	0.2% 	- 	2,350 	2,392 	-1.7% 	-1.7% 	-
Intl 	594 	568 	4.6% 	5.0% 	-0.4% 	2,100 	2,201 	-4.6% 	-2.3% 	-2.3%
WW 	1,177 	1,150 	2.4% 	2.6% 	-0.2% 	4,450 	4,593 	-3.1% 	-2.0% 	-1.1%
ORAL CARE
US 	173 	159 	8.3% 	8.3% 	- 	683 	621 	9.9% 	9.9% 	-
Intl 	264 	233 	13.5% 	14.5% 	-1.0% 	958 	906 	5.7% 	9.6% 	-3.9%
WW 	437 	393 	11.4% 	12.0% 	-0.6% 	1,641 	1,528 	7.4% 	9.7% 	-2.3%
BABY CARE
US 	97 	85 	14.3% 	14.3% 	- 	376 	362 	3.7% 	3.7% 	-
Intl 	310 	336 	-7.8% 	-3.6% 	-4.2% 	1,141 	1,313 	-13.1% 	-7.3% 	-5.8%
WW 	407 	421 	-3.4% 	0.0% 	-3.4% 	1,517 	1,675 	-9.4% 	-4.9% 	-4.5%
WOMEN'S HEALTH
US 	3 	3 	11.8% 	11.8% 	- 	13 	12 	8.2% 	8.2% 	-
Intl 	234 	250 	-6.5% 	-3.1% 	-3.4% 	888 	974 	-8.8% 	-2.9% 	-5.9%
WW 	237 	253 	-6.3% 	-2.9% 	-3.4% 	901 	986 	-8.6% 	-2.7% 	-5.9%
WOUND CARE / OTHER
US 	110 	98 	11.8% 	11.8% 	- 	480 	441 	8.9% 	8.9% 	-
Intl 	65 	57 	12.4% 	13.0% 	-0.6% 	240 	230 	4.1% 	7.3% 	-3.2%
WW 	175 	155 	12.0% 	12.2% 	-0.2% 	720 	671 	7.2% 	8.3% 	-1.1%
TOTAL CONSUMER HEALTH
US 	1,509 	1,470 	2.7% 	2.7% 	- 	6,362 	5,839 	9.0% 	9.0% 	-
Intl 	2,109 	2,097 	0.5% 	1.5% 	-1.0% 	7,691 	8,059 	-4.6% 	-1.3% 	-3.3%
WW 	3,618	$ 	3,567 	1.4% 	2.0% 	-0.6% 	14,053	$ 	13,898 	1.1% 	3.0% 	-1.9%
See footnotes at end of schedule
% Change	% Change

-- 14 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
PHARMACEUTICAL SEGMENT (2,5) 2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
IMMUNOLOGY
US 	2,845	$ 	2,517 	13.0% 	13.0% 	- 	10,175	$ 	9,641 	5.5% 	5.5% 	-
Intl 	1,261 	1,005 	25.4% 	21.1% 	4.3% 	4,880 	4,309 	13.2% 	14.0% 	-0.8%
WW 	4,105 	3,522 	16.6% 	15.3% 	1.3% 	15,055 	13,950 	7.9% 	8.2% 	-0.3%
REMICADE
US 	656 	755 	-13.1% 	-13.1% 	- 	2,508 	3,079 	-18.5% 	-18.5% 	-
US Exports (6) 25 	68 	-62.4% 	-62.4% 	- 	346 	294 	18.0% 	18.0% 	-
Intl 	220 	212 	3.3% 	2.7% 	0.6% 	893 	1,007 	-11.4% 	-8.6% 	-2.8%
WW 	901 	1,035 	-12.9% 	-13.1% 	0.2% 	3,747 	4,380 	-14.4% 	-13.8% 	-0.6%
SIMPONI / SIMPONI ARIA
US 	315 	302 	4.4% 	4.4% 	- 	1,155 	1,159 	-0.3% 	-0.3% 	-
Intl 	261 	213 	22.9% 	18.8% 	4.1% 	1,088 	1,029 	5.8% 	7.0% 	-1.2%
WW 	576 	515 	12.1% 	10.4% 	1.7% 	2,243 	2,188 	2.6% 	3.1% 	-0.5%
STELARA
US 	1,572 	1,194 	31.6% 	31.6% 	- 	5,240 	4,346 	20.6% 	20.6% 	-
Intl 	672 	506 	32.7% 	27.2% 	5.5% 	2,467 	2,015 	22.4% 	22.2% 	0.2%
WW 	2,244 	1,700 	31.9% 	30.3% 	1.6% 	7,707 	6,361 	21.1% 	21.1% 	0.0%
TREMFYA
US 	276 	199 	39.1% 	39.1% 	- 	926 	764 	21.3% 	21.3% 	-
Intl 	105 	71 	48.1% 	40.0% 	8.1% 	421 	248 	69.9% 	67.9% 	2.0%
WW 	382 	270 	41.5% 	39.3% 	2.2% 	1,347 	1,012 	33.2% 	32.7% 	0.5%
OTHER IMMUNOLOGY
US 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
Intl 	2 	2 	-19.7% 	-14.5% 	-5.2% 	11 	10 	6.4% 	12.8% 	-6.4%
WW 	2 	2 	-19.7% 	-14.5% 	-5.2% 	11 	10 	6.4% 	12.8% 	-6.4%
INFECTIOUS DISEASES
US 	470 	435 	7.9% 	7.9% 	- 	1,735 	1,597 	8.6% 	8.6% 	-
Intl 	442 	430 	2.8% 	-2.6% 	5.4% 	1,839 	1,815 	1.3% 	2.2% 	-0.9%
WW 	912 	866 	5.4% 	2.7% 	2.7% 	3,574 	3,413 	4.7% 	5.2% 	-0.5%
EDURANT / rilpivirine
US 	11 	14 	-17.9% 	-17.9% 	- 	44 	50 	-11.2% 	-11.2% 	-
Intl 	236 	209 	13.4% 	6.2% 	7.2% 	920 	812 	13.3% 	11.9% 	1.4%
WW 	248 	222 	11.4% 	4.7% 	6.7% 	964 	861 	11.9% 	10.5% 	1.4%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	433 	390 	11.1% 	11.1% 	- 	1,587 	1,422 	11.6% 	11.6% 	-
Intl 	136 	155 	-12.4% 	-17.1% 	4.7% 	597 	689 	-13.4% 	-10.7% 	-2.7%
WW 	569 	544 	4.4% 	3.1% 	1.3% 	2,184 	2,110 	3.5% 	4.4% 	-0.9%
OTHER INFECTIOUS DISEASES
US 	25 	32 	-20.4% 	-20.4% 	- 	104 	126 	-17.6% 	-17.6% 	-
Intl 	71 	67 	5.2% 	3.3% 	1.9% 	323 	315 	2.6% 	5.6% 	-3.0%
WW 	96 	99 	-3.0% 	-4.3% 	1.3% 	427 	441 	-3.2% 	-1.0% 	-2.2%
% Change 	% Change

-- 15 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
NEUROSCIENCE
US 	806 	747 	7.9% 	7.9% 	- 	3,091 	2,919 	5.9% 	5.9% 	-
Intl 	892 	819 	9.0% 	6.2% 	2.8% 	3,457 	3,409 	1.4% 	2.2% 	-0.8%
WW 	1,698 	1,566 	8.5% 	7.0% 	1.5% 	6,548 	6,328 	3.5% 	3.9% 	-0.4%
CONCERTA / Methylphenidate
US 	33 	37 	-9.7% 	-9.7% 	- 	183 	233 	-21.4% 	-21.4% 	-
Intl 	120 	115 	4.2% 	1.4% 	2.8% 	439 	463 	-5.1% 	-4.5% 	-0.6%
WW 	153 	152 	0.9% 	-1.2% 	2.1% 	622 	696 	-10.6% 	-10.2% 	-0.4%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	610 	564 	8.1% 	8.1% 	- 	2,314 	2,107 	9.8% 	9.8% 	-
Intl 	355 	308 	15.7% 	10.8% 	4.9% 	1,339 	1,224 	9.4% 	9.1% 	0.3%
WW 	965 	871 	10.8% 	9.0% 	1.8% 	3,653 	3,330 	9.7% 	9.6% 	0.1%
RISPERDAL CONSTA
US 	76 	77 	-2.5% 	-2.5% 	- 	296 	314 	-5.9% 	-5.9% 	-
Intl 	92 	82 	11.0% 	7.7% 	3.3% 	346 	374 	-7.5% 	-6.9% 	-0.6%
WW 	167 	160 	4.4% 	2.7% 	1.7% 	642 	688 	-6.8% 	-6.4% 	-0.4%
OTHER NEUROSCIENCE
US 	88 	70 	27.4% 	27.4% 	- 	298 	266 	12.4% 	12.4% 	-
Intl 	326 	314 	3.7% 	3.1% 	0.6% 	1,334 	1,349 	-1.1% 	0.7% 	-1.8%
WW 	414 	383 	8.0% 	7.5% 	0.5% 	1,632 	1,614 	1.1% 	2.6% 	-1.5%
ONCOLOGY
US 	1,469 	1,153 	27.4% 	27.4% 	- 	5,092 	4,299 	18.5% 	18.5% 	-
Intl 	1,965 	1,563 	25.7% 	20.9% 	4.8% 	7,275 	6,393 	13.8% 	14.0% 	-0.2%
WW 	3,434 	2,716 	26.4% 	23.7% 	2.7% 	12,367 	10,692 	15.7% 	15.8% 	-0.1%
DARZALEX
US 	692 	444 	55.6% 	55.6% 	- 	2,232 	1,567 	42.4% 	42.4% 	-
Intl 	561 	385 	45.4% 	41.3% 	4.1% 	1,958 	1,430 	36.9% 	38.0% 	-1.1%
WW 	1,253 	830 	50.9% 	49.0% 	1.9% 	4,190 	2,998 	39.8% 	40.3% 	-0.5%
ERLEADA
US 	176 	103 	70.8% 	70.8% 	- 	583 	297 	96.1% 	96.1% 	-
Intl 	64 	13 	* 	* 	* 	176 	35 	* 	* 	*
WW 	241 	116 	* 	* 	* 	760 	332 	* 	* 	*
IMBRUVICA
US 	492 	392 	25.8% 	25.8% 	- 	1,821 	1,555 	17.1% 	17.1% 	-
Intl 	625 	483 	29.3% 	24.8% 	4.5% 	2,307 	1,856 	24.3% 	25.1% 	-0.8%
WW 	1,117 	875 	27.8% 	25.3% 	2.5% 	4,128 	3,411 	21.0% 	21.5% 	-0.5%
VELCADE
US 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
Intl 	97 	115 	-15.2% 	-18.5% 	3.3% 	408 	751 	-45.7% 	-45.8% 	0.1%
WW 	97 	115 	-15.2% 	-18.5% 	3.3% 	408 	751 	-45.7% 	-45.8% 	0.1%
ZYTIGA / abiraterone acetate
US 	89 	194 	-54.3% 	-54.3% 	- 	373 	810 	-54.0% 	-54.0% 	-
Intl 	533 	483 	10.2% 	4.3% 	5.9% 	2,097 	1,985 	5.6% 	4.7% 	0.9%
WW 	622 	677 	-8.3% 	-12.5% 	4.2% 	2,470 	2,795 	-11.6% 	-12.3% 	0.7%
OTHER ONCOLOGY
US 	20 	19 	2.6% 	2.6% 	- 	83 	70 	19.2% 	19.2% 	-
Intl 	86 	84 	1.5% 	-2.1% 	3.6% 	330 	336 	-1.9% 	-1.4% 	-0.5%
WW 	105 	104 	1.7% 	-1.2% 	2.9% 	413 	407 	1.7% 	2.2% 	-0.5%
PULMONARY HYPERTENSION
US 	592 	388 	52.5% 	52.5% 	- 	2,133 	1,684 	26.6% 	26.6% 	-
Intl 	273 	235 	16.8% 	12.5% 	4.3% 	1,015 	939 	8.2% 	8.0% 	0.2%
WW 	865 	623 	39.0% 	37.4% 	1.6% 	3,148 	2,623 	20.0% 	20.0% 	0.0%
OPSUMIT
US 	279 	185 	52.1% 	52.1% 	- 	1,008 	766 	31.7% 	31.7% 	-
Intl 	173 	143 	21.2% 	16.9% 	4.3% 	631 	562 	12.3% 	12.3% 	0.0%
WW 	452 	326 	38.6% 	36.7% 	1.9% 	1,639 	1,327 	23.5% 	23.5% 	0.0%
UPTRAVI
US 	263 	178 	48.2% 	48.2% 	- 	955 	714 	33.8% 	33.8% 	-
Intl 	38 	30 	25.5% 	20.1% 	5.4% 	138 	105 	30.9% 	30.5% 	0.4%
WW 	301 	208 	44.9% 	44.1% 	0.8% 	1,093 	819 	33.5% 	33.4% 	0.1%
OTHER PULMONARY HYPERTENSION
US 	49 	26 	84.9% 	84.9% 	- 	169 	205 	-17.6% 	-17.6% 	-
Intl 	63 	62 	2.4% 	-1.2% 	3.6% 	247 	272 	-9.2% 	-9.4% 	0.2%
WW 	112 	88 	26.6% 	24.1% 	2.5% 	416 	476 	-12.8% 	-12.9% 	0.1%
CARDIOVASCULAR / METABOLISM / OTHER
US 	935 	930 	0.6% 	0.6% 	- 	3,509 	3,734 	-6.0% 	-6.0% 	-
Intl 	317 	327 	-2.6% 	-5.4% 	2.8% 	1,369 	1,458 	-6.1% 	-4.8% 	-1.3%
WW 	1,253 	1,256 	-0.2% 	-1.0% 	0.8% 	4,878 	5,192 	-6.0% 	-5.7% 	-0.3%
XARELTO
US 	629 	609 	3.1% 	3.1% 	- 	2,345 	2,313 	1.4% 	1.4% 	-
Intl 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
WW 	629 	609 	3.1% 	3.1% 	- 	2,345 	2,313 	1.4% 	1.4% 	-
INVOKANA / INVOKAMET
US 	159 	125 	27.7% 	27.7% 	- 	564 	536 	5.2% 	5.2% 	-
Intl 	58 	52 	11.5% 	8.9% 	2.6% 	231 	199 	16.3% 	17.6% 	-1.3%
WW 	217 	177 	22.9% 	22.1% 	0.8% 	795 	735 	8.2% 	8.6% 	-0.4%
PROCRIT / EPREX
US 	62 	118 	-46.9% 	-46.9% 	- 	277 	505 	-45.1% 	-45.1% 	-
Intl 	66 	65 	2.0% 	-1.1% 	3.1% 	274 	285 	-3.8% 	-3.6% 	-0.2%
WW 	129 	183 	-29.5% 	-30.6% 	1.1% 	552 	790 	-30.2% 	-30.1% 	-0.1%
OTHER
US 	85 	78 	9.4% 	9.4% 	- 	323 	380 	-15.1% 	-15.1% 	-
Intl 	194 	209 	-7.6% 	-10.3% 	2.7% 	864 	974 	-11.3% 	-9.7% 	-1.6%
WW 	278 	286 	-3.0% 	-5.0% 	2.0% 	1,186 	1,353 	-12.4% 	-11.2% 	-1.2%
TOTAL PHARMACEUTICAL
US 	7,116 	6,169 	15.3% 	15.3% 	- 	25,735 	23,874 	7.8% 	7.8% 	-
Intl 	5,152 	4,379 	17.7% 	13.5% 	4.2% 	19,837 	18,324 	8.3% 	8.8% 	-0.5%
WW 	12,268	$ 	10,548 	16.3% 	14.6% 	1.7% 	45,572	$ 	42,198 	8.0% 	8.2% 	-0.2%
See footnotes at end of schedule
% Change 	% Change

-- 16 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
MEDICAL DEVICES SEGMENT (2,5) 2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
INTERVENTIONAL SOLUTIONS
US 	433	$ 	377 	14.8% 	14.8% 	- 	1,452 	1,443 	0.6% 	0.6% 	-
Intl 	460 	398 	15.7% 	10.8% 	4.9% 	1,594 	1,554 	2.6% 	2.0% 	0.6%
WW 	893 	774 	15.3% 	12.8% 	2.5% 	3,046 	2,997 	1.6% 	1.3% 	0.3%
ORTHOPAEDICS
US 	1,352 	1,369 	-1.3% 	-1.3% 	- 	4,779 	5,319 	-10.2% 	-10.2% 	-
Intl 	839 	904 	-7.3% 	-11.3% 	4.0% 	2,984 	3,520 	-15.2% 	-15.4% 	0.2%
WW 	2,191 	2,273 	-3.7% 	-5.3% 	1.6% 	7,763 	8,839 	-12.2% 	-12.3% 	0.1%
HIPS
US 	229 	230 	-0.7% 	-0.7% 	- 	793 	863 	-8.2% 	-8.2% 	-
Intl 	143 	147 	-2.2% 	-5.8% 	3.6% 	487 	575 	-15.3% 	-15.1% 	-0.2%
WW 	372 	377 	-1.3% 	-2.7% 	1.4% 	1,280 	1,438 	-11.0% 	-11.0% 	0.0%
KNEES
US 	216 	239 	-9.5% 	-9.5% 	- 	743 	889 	-16.4% 	-16.4% 	-
Intl 	129 	156 	-17.2% 	-20.6% 	3.4% 	427 	591 	-27.8% 	-28.0% 	0.2%
WW 	345 	395 	-12.5% 	-13.9% 	1.4% 	1,170 	1,480 	-21.0% 	-21.1% 	0.1%
TRAUMA
US 	454 	413 	10.0% 	10.0% 	- 	1,648 	1,652 	-0.2% 	-0.2% 	-
Intl 	268 	273 	-2.0% 	-6.2% 	4.2% 	966 	1,068 	-9.6% 	-9.7% 	0.1%
WW 	722 	686 	5.2% 	3.6% 	1.6% 	2,614 	2,720 	-3.9% 	-3.9% 	0.0%
SPINE, SPORTS & OTHER
(7)
US 	453 	488 	-7.1% 	-7.1% 	- 	1,595 	1,915 	-16.7% 	-16.7% 	-
Intl 	299 	329 	-9.2% 	-13.6% 	4.4% 	1,104 	1,286 	-14.1% 	-14.6% 	0.5%
WW 	752 	817 	-7.9% 	-9.7% 	1.8% 	2,699 	3,201 	-15.7% 	-15.9% 	0.2%
SURGERY
US 	1,002 	961 	4.3% 	4.3% 	- 	3,249 	3,828 	-15.1% 	-15.1% 	-
Intl 	1,427 	1,481 	-3.7% 	-5.9% 	2.2% 	4,983 	5,673 	-12.2% 	-11.2% 	-1.0%
WW 	2,429 	2,442 	-0.5% 	-1.9% 	1.4% 	8,232 	9,501 	-13.4% 	-12.8% 	-0.6%
ADVANCED
US 	456 	428 	6.5% 	6.5% 	- 	1,535 	1,637 	-6.2% 	-6.2% 	-
Intl 	660 	647 	2.1% 	-0.9% 	3.0% 	2,304 	2,458 	-6.2% 	-5.6% 	-0.6%
WW 	1,116 	1,076 	3.8% 	2.0% 	1.8% 	3,839 	4,095 	-6.2% 	-5.8% 	-0.4%
GENERAL
US 	546 	534 	2.5% 	2.5% 	- 	1,714 	2,192 	-21.8% 	-21.8% 	-
Intl 	767 	834 	-8.1% 	-9.8% 	1.7% 	2,679 	3,215 	-16.7% 	-15.5% 	-1.2%
WW 	1,312 	1,366 	-4.0% 	-5.0% 	1.0% 	4,392 	5,406 	-18.8% 	-18.0% 	-0.8%
VISION
US 	397 	428 	-7.3% 	-7.3% 	- 	1,557 	1,794 	-13.2% 	-13.2% 	-
Intl 	679 	713 	-4.7% 	-6.2% 	1.5% 	2,362 	2,830 	-16.5% 	-16.2% 	-0.3%
WW 	1,076 	1,141 	-5.7% 	-6.6% 	0.9% 	3,919 	4,624 	-15.2% 	-15.1% 	-0.1%
CONTACT LENSES / OTHER
US 	289 	311 	-7.4% 	-7.4% 	- 	1,213 	1,304 	-7.0% 	-7.0% 	-
Intl 	507 	522 	-2.7% 	-4.1% 	1.4% 	1,781 	2,088 	-14.7% 	-14.4% 	-0.3%
WW 	796 	833 	-4.4% 	-5.3% 	0.9% 	2,994 	3,392 	-11.7% 	-11.5% 	-0.2%
SURGICAL
US 	108 	117 	-7.1% 	-7.1% 	- 	344 	490 	-29.7% 	-29.7% 	-
Intl 	172 	191 	-10.3% 	-12.0% 	1.7% 	581 	742 	-21.7% 	-21.5% 	-0.2%
WW 	280 	309 	-9.1% 	-10.1% 	1.0% 	925 	1,232 	-24.9% 	-24.7% 	-0.2%
TOTAL MEDICAL DEVICES
US 	3,184 	3,135 	1.5% 	1.5% 	- 	11,036 	12,384 	-10.9% 	-10.9% 	-
Intl 	3,405 	3,497 	-2.6% 	-5.5% 	2.9% 	11,923 	13,579 	-12.2% 	-11.8% 	-0.4%
WW 	6,589	$ 	6,632 	-0.7% 	-2.2% 	1.5% 	22,959	$ 	25,963 	-11.6% 	-11.4% 	-0.2%
* Percentage greater than 100% or not meaningful 	(6) Reported as U.S. sales
(1) Operational growth excludes the effect of translational currency 	(7) Previously referred to as Spine & Other
(2) Unaudited
(3) Previously referred to as Consumer
(4) Previously referred to as Beauty
(5) Certain prior year amounts have been reclassified to conform to current year product disclosures
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
% Change 	% Change

-- 17 of 17 --